About Alimera Sciences (ALIM)
Alimera Sciences, Inc. is a commercial-stage global pharmaceutical company. The Company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for no... Read more
- USD3.16
- USD3.19
- USD2.94
- USD6.25
- -12.30%
- 59M
- 75.00
- 58.73k
- 163M
- 1.30
- -45.30%
- 19.30%
Stock News
34 minutes ago
Down More Than 20% in a Week, This Elite Dividend Stock is Looking Like a Screaming Bargain
Yahoo
47 minutes ago
Rigetti Computing Awarded DARPA IMPAQT Contract to Advance Quantum Algorithms for Solving Combinatorial Optimization Problems
Yahoo
1 hour ago
The Ratings Game: Airbnb’s stock slumps after KeyBanc downgrade on expectations for a pullback in leisure travel
MarketWatch
1 hour ago
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Yahoo
Unlock More Stock Analysis & Reports
Access to easy in-depth stock analysis and reports from Refinitiv with analyst estimates on share price movements.
